Will AstraZeneca's Earnings  Outperform?

Will AstraZeneca's Earnings Outperform?

2022-01-28 • Updated

This week, the stock of AstraZeneca was one of the most traded instruments in FBS Trader! It was even more popular than the stock of Tesla. There has been news that grabbed the attention of traders this week. It’s also worth mentioning the earnings of a company coming out this Friday. What should you know ahead of it?

Earnings expected

EPS = 0.62 (vs. 0.47 in Q3 2020)

Revenue = 9520 (vs. 6578 in Q3 2020)

The release of financial results is expected on November 12, at 13:45 GMT+2.

What affects the company’s performance?

The destiny of the Anglo-Swedish drug giant has been complicated since the start of the Covid-19 pandemic. You may have heard of the news about the vaccine that causes blood clots. As the cases were linked to AstraZeneca’s vaccine, several countries restricted its use. Luckily for AstraZeneca, the European Medicines Agency (EMA) and the World Health Organization (WHO) both confirmed that the vaccine was safe and effective. The organizations said that the number of blood clots was extremely rare. Another challenging factor for the company this year was linked to the production problems. AstraZeneca cut its vaccine deliveries to the EU by half, reportedly due to problems at its plants and delayed testing of a batch of vaccines.

However, the company managed to stabilize its performance in 2021. Last week, it announced the creation of a new division for vaccines and antibody therapies. Vaccines are seen as not a traditional area for the company, so optimization of its structure certainly helps with business processes. Another positive news is the approval of the drug maker’s antibody cocktail against Covid-19 in Australia. Now, the mixture is awaiting a review by the European Medicines Agency.   

The first half of the year was the golden time for the company. The Covid vaccine resulted in an outstanding improvement of AstraZeneca’s financial results making 9% out of +18% of the total revenue growth in the first half of the year. 

3432.png

Apart from the vaccine, AstraZeneca has been working on cancer drugs – Lynparza, Tagrisso, Imfinzi, and diabetes medicine. Their sales have been rapidly growing as well.  Higher demand for Tagrisso in the United States amid the broad-based adjuvant therapy for treating lung cancer patients may improve the company’s financial results as well.  Other medical treatments are also likely to have contributed to sales growth in the third quarter.

45324.png

#AZN.UK stock

The stock of AstraZeneca has been moving within an uptrend. The breakout of the 9500 level will be crucial, as it will lead to the rise to July's all-time high of 10 088. If stock's price breaks below the support of 9240, it will indicate a bearish scenario with the next potential target of 9000. 

#AZN.UKDaily.png

Bottom line

Summing up, AstraZeneca has a great potential to post good financial results for the third quarter. Its business structure is accelerating and new facilities are developing. Also, it produces necessary drugs for the treatment of Covid-19 and other severe diseases. The demand for this medicine has been growing last quarter and it may attribute to the strong financial report on Friday. Follow the release on Friday at 13:45 GMT+2!

Don't know how to trade stocks? Here are some simple steps.

  1. First of all, be sure you’ve downloaded FBS Trader app or Metatrader 5. FBS allows you to trade stocks only through this software.
  2. Open an account in FBS Trader or the MT5 account in your personal area.
  3. Start trading!

Similar

Many Reasons to Buy Disney Stock
Many Reasons to Buy Disney Stock

People all over the world love kind and colorful Disney cartoons. What if we say that you can both adore the pictures and trade stocks of the company that creates them?

How Alibaba Deals with Troubled Times?
How Alibaba Deals with Troubled Times?

The e-commerce giant has recently faced a lot of pressure, starting from global uncertainty in China amid lockdowns and geopolitics. The company has been added to the US SEC (Securities and Exchange Commission) delisting queue. Finally, there’s an earnings report coming on August 4. Let’s discuss everything and prepare for the next move.

Inovio to Plunge Ahead of Earnings Report
Inovio to Plunge Ahead of Earnings Report

About the company Inovio Pharmaceuticals Inc (INO) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines to treat and prevent various cancers and infectious diseases…

Latest news

UK: No Longer a Leading Economy
UK: No Longer a Leading Economy

The current situation is terrible, and the future is worse for the United Kingdom. Will the British pound withstand the challenges that await the UK economy, or will it collapse?

Deposit with your local payment systems

Be on top of your game

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.

Callback

A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

Beginner Forex book

Beginner Forex book will guide you through the world of trading.

Beginner Forex book

The most important things to start trading
Enter your e-mail, and we will send you a free Beginner Forex book

Thank you!

We've emailed a special link to your e-mail.
Click the link to confirm your address and get Beginner Forex book for free.

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera